We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EDEN Eden Research Plc

-0.10 (-2.33%)
06 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -2.33% 4.20 839,996 13:38:41
Bid Price Offer Price High Price Low Price Open Price
4.00 4.40 4.30 4.10 4.30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -11.90 26.67M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:41:01 O 10,117 4.215 GBX

Eden Research (EDEN) Latest News

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
07/12/202302:52Eden Research15,964
21/6/202311:05The sterile garden of Eden123
31/3/202213:47Eden....Onward and Upwards!50
29/3/202215:04Eden Research14
29/3/202213:36Eden Research - Who Is Behind Thallo Eco Products Corp?27

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-06 15:41:024.2210,117426.43O
2023-12-06 14:40:574.221,60267.52O
2023-12-06 14:40:024.40227,0019,988.04O
2023-12-06 14:36:504.13242,1349,988.03O
2023-12-06 13:38:274.18119,3884,988.03O

Eden Research (EDEN) Top Chat Posts

Top Posts
Posted at 06/12/2023 08:20 by Eden Research Daily Update
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.30p.
Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £26,667,626.
Eden Research has a price to earnings ratio (PE ratio) of -11.90.
This morning EDEN shares opened at 4.30p
Posted at 05/12/2023 12:15 by kenmitch

It’s probably my fault that you didn’t cash in after thst Sunday Mail tip. I posted that I expected the share price to double on that news but instead it hardly moved and that, and the reason why it didn’t, is why I unwisely and wrongly posted against buying.Apologies for that IF it influenced your decision not to buy. That reason that held the share price down was because a big investor used that tip as a chance to escape. BUT after that the share did behave exactly as I forecast, both here and on Mike Walters site, as I predicted it would and why, at the time.

I.e VERY clever work by Cenkos and EDEN in somehow persuading that Sunday Mail journalist to tip EDEN. I forecast that that would lead to a temporary big share price rise that would enable EDEN to get a fund raising away at well above that 3p or so pre tip price.

(The start of those gains WAS a big trading buy opportunity. I messed that up by buying too late and selling too soon before the 12p peak so only got 30% gain, but cleverer traders could have tripled their money, and fans here who are so totally convinced could have cashed in by buying a trading stake and then taking a big profit too).

I posted that after that fund raising the share price was very likely to fall all the way back to where it was before that clever and successful hyping. And so it has.

What now? It’s dead money imo for a good while yet as EDEN share price will now only go up on Ecovelex approval news and then permanently if at long long long long last that is followed by meaningful sales. It’s then and not now that I’ll invest in EDEN again. That’s when the share price could well rocket.

Separately Brucie. I’ve noticed that what is happening right now is what has happened before at the end of bear markets. I.e on days when the indexes are down, especially so the FTSE100, a lot of bombed out shares, including our big dividend paying shares and Investment Trusts, are going up on down days. That’s a very positive sign.

E.g EBOX which fell to way oversold 45p is back to 58p and up again today with FTSE100 down 50 points, after their reassuring results and held big covered dividend. So whatever happens to your EDEN stake,VERY high chance of very happy days for your portfolio ahead.
Posted at 04/12/2023 15:56 by investingisatrickygame

I think you're being too harsh. Eden didn't have the regulatory footprint years ago, or the label extension opportunities. That has and is changing right now.

They didn't have a global seed product back then; they do now and the recent online investor conference explained that when the current incumbent is soon removed, there is nothing to repel birds, save Ecovelex. This will deliver significant sales for Eden.

Furthermore, why would one company spend a not insignificant sum trialling 140 locations for Eden's soon to be announced and contracted, global insecticide. Because they clearly believe that insecticide might/will work for them globally.

It seems to me you are making judgements today, based on the past, but the past is not where Eden is today. Review where we are today and make a judgement based on that. If we all based Eden on the past, we wouldn't be invested, would we!
Posted at 25/11/2023 08:53 by attyg
Alchemy wrote:
Buying opps until late next spring if regulators are very dilatory .
Buying on dips will take courage ,

In my view, again in MY view - buying does not take courage - just money.

Sadly I am more than skint and now obliged to buy another car as a crash has made my current car "uneconomical to repair" - oh well.

Timing in so many matters can be critical.

Sure, I do not expect any takeover - well not for a couple of years at least.
News on an insecticide deal(s) have been flagged as Q1 2024.
Trading statement possibly around 18 Dec or mid Jan latest.
However, ecovalex EA could come at any day. Californian approval could come at any day.
Of course one can take the view that either or both might add a penny at best to the share price I take the view that it could propel the share price much higher, especially as it will be followed with a buy note from Cenkos containing projections of profit (and cash positive) in 2024 and beyond.
Naturally a cautious (sensible) investor might accept a higher cost base, of course the counter argument is, how low can the share price fall without news till mid Jan, when we are at 4 bloody p?

No-one should be here if they conclude Eden is full of smoke and mirrors.
If one believes Eden is on the cusp, then the current share price is an incredible buying opportunity that does not take courage, but money and a little patience to bring substantial rewards.
The share trades yesterday looked more like bed and breakfasts or T20 rollovers.
What is evident is that there is not a great amount of liquidity - so some serious buying will propel the share price north

Gotta go for a walk with grandchild
Posted at 20/11/2023 17:09 by attyg
Just back from my travels to watch Scotland leak three, yes, THREE very poor goals to Noway without Haaland playing - can't remember when Scotland last leaked three goals at Hampden - if anyone knows, please do not remind me. Anyhow, we're joining England in Germany next June, so I don't care.

Alchemy wrote:

"I still ask myself - “Was the Ecovolex order a full grown-up order for delivery “? . Or orchestrated at fund raising time?"

Sean spoke in a recent video of how the size of the order was such that the Board had to consider if they could go ahead without recourse to a fund raise - and while it was concluded that it was possible, the Board nevertheless deemed the prudent course of action was to raise additional funds.
No mention was made regarding the size/value of the order - but I guess it must be significant for Eden to generate a need for further funding.

I say, if you don't trust Sean and or the Board - sell up.

It is definitely possible that Eden receives neither EA approval for Ecovelex in any country this year and possible too, that California does not grant approval for mevalone.

However, that may not equate to no sales in 2023.
Corteva may take some of the order before the year is out and I understand our Californian mevalone distributor is ready and may have placed an order for mevalone.

I sense you are impatient for the share price to travel in a northerly direction - and at some speed. While most people who have experience in Eden would retort - he doesn't have any experience of Eden time, does he - guffaw. I am inclined to point out that each approval Eden obtains for Ecovalex and Californian approval for mevalone will (I understand) generate a need for Cenkos/Cavendish to update the market and such update will require them to markedly amend the financial projections.

When sentiment changes with Eden, I expect the share price movement to meet your needs.
Of course, just sell up if you think Sean and or the Board tell porkies.
Posted at 17/11/2023 12:52 by investingisatrickygame

from the recent Half-year report Eden states

"On review of the estimated timeline for product development and given the slow pace of development to commercialisation of products in the crop protection industry, the Directors have forecasted that most of the future revenues for product development projects will start at the end of the current forecasting timeline of 2030"

This is why I only focus on 1-5. We know, those of us that understand Eden, what the timelines are from concept to commercialisation. So unless Eden has something in somewhat advanced trails, it is down to Mevalone, Cedroz, Ecovelex & our insecticide to deliver commercial revenues this next three years and to enhance revenue through label extensions and new regulatory approvals in new countries/territories.

This to my mind, right or wrong, makes Eden quite easy to understand now for the period stated. They have raised their recent cash and will spend it to achieve these goals. This is qualified in their 28th July 2023 Capital Raising RNS. hxxps:// This they will support with some additional staff.

For any new investor coming into Eden, this perfectly explains Eden's function in Crop Protection which is to conceptualise (sometimes with a partner as with Ecovelex) and to get said new product to a successful regulatory approval. Demand then follows to be the seller of Eden's products.

The footprint for Eden within the 3 years will hopefully expand significantly making Eden very valuable which in turn will hopefully be properly reflected in the share price. Knowing this highlight's just how cheap Eden's shares are at this moment in time & reflects a great buying opportunity for those that share this view and have funds available.
Posted at 10/11/2023 11:56 by attyg
Cheesus Alchemy,

It stresses me I have no funds to be adding now!

Time and timing has and remains a real issue with Eden.

Regulators work at - I was going to say their own pace, but I don't know they even do that - they certainly do not follow their own guidelines.
Anyhow, Eden will get the approvals - and the fund raise (which I initially thought was ill judged) enables all of us and the Company to be confident it has enough dosh to get through to cash positive trading plus accelerate other aspects of the business.

If you are reading the detailed Cenkos note, bear in mind the sales numbers are what I call rubbish. As you know Eden has entered into contracts with the likes of Corteva, Sipcam and Eastman. The figures quoted by Cenkos are the minimum sales values the distributors are contractually obliged to take - you can then use your common sense and make a judgement call on Eden's possible sales with reference to Cenkos' market size and your own thoughts as to Eden's probable market share.

Remember, despite moving away from an overhead light Royalty sales model, Eden remains, and is likely to remain, relatively light on overhead cost base which when combined with an increasingly high GP% provides Eden with substantial profit leverage with little additional sales - in other words, Eden does not require much more than £6m sales to be break even.
Now, cogitate on what sales Eden could should expect in two and four years from now.

An exceptional investment opportunity.

However, as always - do your own research
Posted at 19/10/2023 16:09 by supersonico
Repost 14133 reminder of Insecticide Chronicles.

"That product is currently under going field trials with potential partners in fact I'm very pleased to say one of those partners is running in excess of 80 different field trials this year".

supersonico - 09 Feb 2023 - 10:21:02 - 13759 of 14133 Eden Research - EDEN
Annual Insecticide / development update...2019-2023

15 January 2019;
The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging.

14 January 2020
Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture."

11 February 2021
Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients.

2nd March 2022
Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden.

10 January 2023
Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.
Posted at 18/10/2023 08:41 by investingisatrickygame
If we take a three year view from today based on how long many have been invested and acknowledging the recent capital raise and its goals, we can come to a few conclusions.

Given the time it takes to conceive a product and deliver a solution to commercialisation, it is more than 3 years. So no more new products to commercialise for the next three years if starting today.

That leaves us with a clear view of what will generate value for Eden and it's shareholders in the next three years, namely, product sales of Mevalone, Cedroz, Ecovelex and the anticipated Insecticide.

We can reasonably assume through our own knowledge and the stated goals of the capital raise that these products during the course of the next three years will acquire label extensions and approvals in new territories, perhaps Asia as suggested by the Company. This will further increase sales, but hopefully and as the Company has also stated, hope to see more timely regulatory approvals based on the known and approved (in many territories already) same three AI's to comprise a product. We/Eden will also have the support of major Ag companies, namely Corteva and presumably, ANO for the Insecticide which should expedite, IMO, approvals and sales.

So as shareholders, we can reasonably expect, can we not, that the Company has a clear vision of a range of anticipated revenues and profit scenarios from which we can deduce a future share price range during this forward period. This is what investors need to see, is it not? The Company needs to paint a picture for investors based on these scenarios in order to encourage investment and show potential investment returns.

We provide Cenkos with conservative forecasts and we can reasonably assume that these forecasts and further potential are discussed with institutions to encourage capital investment with a potential healthy return.

Working on a P/E of 20-30, investors should be able to see the possibility, the vision and then invest in Eden knowing that their own vision of being a global leader in sustainable crop protection.

Not everybody can work it out, so it needs spelling out. With a sound product base and three years between the last two capital raises, it is a reasonable window to consider and one financially that Eden will forecast.

Are there any variables that could change valuing the business from above during this timeframe? The only one I can see is if Eden already has products in development that are maybe 50%-75% plus through their development cycle and we are as yet, unaware of them and therefore, they too could come to commercialisation within the three years.

Finally, I would imagine that if Eden has this stable of products developed as detailed above (as and when the Insectidide deal is announced and Ecovelex has regulatory approval) and IF Eden were still to be sat at this very low share price point, then Eden would surely, IMO, be vulnerable to a bid as they would have a decent regulatory footprint, a number of label extensions with more to come and a value that doesn't reflect its overall footprint.

And I didn't even mention Sustaine as a separate entity to commercialise.

Eden is definitely in a different place now, like never before and value has to out.
Posted at 05/10/2023 07:53 by monet
Well Completion of Conditional Placing at 6.5p against a share price today of 4.9p.
so well done for getting it away.

A Reality check ravenna23. So you lied, perhaps you have denial issues too? LOL

(ravenna23 - 28 Sep 2023 - 11:16:16 - 15366 of 15439 Eden Research - EDEN
I do post on other boards, but with different user IDs) Beware of sheep in Wolves clothing.

(ravenna23 - 28 Sep 2023 - 08:29:49 - 15340 of 15438 Eden Research - EDEN
A reality check for all of you dreamers. Eden only raised 1.5m, that is only a few months cash (salary for directors). There has been no further mention of the 9m from EIS schemes. This is probably due to the fact that 3 months after half year end there are still no accounts. Why, because I doubt given Edens financial position even the most optimistic auditor could declare them as a going concern, namely enough money to last a year. No reputable EIS manager will put money into such a company. Your only hope now is that Corteva are feeling generous and buy out Eden. This will be at a lower price than you just paid at the cap raise. However I still think Edens will go into administration or be taken private. May have got the date wrong, but yet to be proved wrong.
The directors of Eden are doing shareholders no favours whatsoever. Hopium is the only thing for holders.)
Posted at 21/9/2023 09:14 by investingisatrickygame
We will have to wait and see over time if Eden get's taken out, but

1) Profit doesn't seem to be a requirement to takeover, example cited
2) Collective collaboration can still exist, even if Eden and its IP, know-how & products have new owners
3) Consolidation can still take place, even if not independent
4) Human and corporate nature tells us that people and business do not like others to have what they don't have themselves. As such, I'd imagine a competitor would rather own and control point 2, rather than let Eden thrive independently and answer to Eden's tune and margins

Time will tell. I don't know if Eden will get taken out, but if Ecovelex is to be one of several seeds and if the insecticide is as suggested, it makes Eden highly attractive through its know-how and ability to develop relevant bio products.

In my opinion, one major threat to Eden staying independent is money. Eden doesn't have vast amounts of cash to expedite product development and regulatory approvals as quickly as they may like. If Eden's Active Ingredients have infinite possibilities as Sean declared in a presentation earlier this year, then it is natural to assume that product development is being held back by a lack of cash.

Big Ag doesn't have that constraint. If big Ag recognises the opportunities in Eden's AI's that Eden does, then the possibility exists for Eden to be taken out, regardless of profits, so that a strong portfolio of products can come to market quicker., satisfying farmers, consumers & regulators alike.
Eden Research share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |